Seer Q3 2026 earnings

SEER · 2026-11-10 16:22 AMC ET · 8-K on SEC

Revenue increased sequentially to $4.0 million, but the company cut full-year guidance to $13.5 million–$14.5 million due to extended sales cycles.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$3.98M-3%+29%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product$2.76M+0%69%Sales of Proteograph instruments and consumable kits
Service$1.06M+16%27%—
Related party$90K-70%2%—
Other$67K-56%2%—

Margins and costs

  • Gross margin 47% (prior 49%, change -2 pp)
  • Operating expenses $16.55M (-23% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0% (prior-year 0%, year-to-date 0.1%)
  • Non-GAAP bridge Free cash flow is a non-GAAP financial measure, defined as net cash used in operating activities less net purchases of property and equipment.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and investments$198.1M$209.5M$198.1M-5.4%
Weighted-average shares outstanding55.56M55.30M56.31M+0.5%
Free cash flow (nine months)-$34.8M-$25.3M-$39.4M+11.5%

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$13.5M–$14.5M$16M–$18M-2 pp at midpoint

What drove it

  • Revenue story Revenue increased 29% sequentially to $4.0 million, driven by product and service growth, but declined 3% year-over-year to $4.1 million.
  • EPS story Net loss per share improved to -$0.25 from -$0.33 YoY, driven by lower operating expenses and a slight decrease in weighted-average shares.
  • One-off check No one-off items identified in the release.

The good

  • Revenue increased sequentially by 29% to $4.0 million
  • Operating expenses decreased 23% YoY to $16.55 million
  • Cash and cash equivalents and investments remained strong at $198.1 million

The bad

  • Gross margin declined 2 pp YoY to 47%
  • Full-year revenue guidance cut to $13.5M–$14.5M due to extended sales cycles

The ugly

  • none

Open questions

  • What is the expected timing and outcome of the ITC's final determination on the Nanomics exclusion order?
  • How will the company reach cash flow breakeven under the current operating plan?
Full release

Seer (SEER) earnings release, November 10, 2026

Seer, Inc. (SEER) · Form 8-K, Item 2.02 · Filed · SEC filing

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended September 30, 2026.

Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer also updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.

“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform,” said Omid Farokhzad, Chair and Chief Executive Officer. “Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”

Recent Business and Corporate Highlights

• Established customers continued to purchase consumables, including accounts with purchases across multiple consecutive quarters. Several new large pharmaceutical customers purchased instruments and consumables this year, supporting opportunities for larger studies and broader use within customer accounts.

• Announced on October 29 that the Special Committee of Seer’s Board of Directors completed its review and Seer will remain an independent public company, reinforcing the Company’s continued commitment to innovation, service and customer support.

• Announced on November 5 that, following Nanomics Biotechnology Co., Ltd.’s withdrawal from defending the U.S. International Trade Commission (“ITC”) investigation brought by Seer and Brigham and Women’s Hospital, the ITC’s investigative staff recommended granting the full exclusion and cease-and-desist orders requested. The Commission’s final determination remains pending and is expected by year-end.

Scientific Highlights

• Publications, preprints and reviews describing research conducted using Proteograph reached 116, up from 95 at the last quarterly update, highlighting the discoveries researchers are advancing across a broad range of applications.

• PRECISE-SG100K investigators presented preliminary findings at HUPO 2026 from 9,658 plasma samples. Using Proteograph with Thermo Fisher’s Orbitrap Astral mass spectrometer, they quantified approximately 8,800 protein groups across the study and 88,000 peptides per sample.

• Proteograph’s nanoparticle enrichment substantially expands the plasma proteome available for discovery. Published studies and customer presentations using matched plasma samples have repeatedly shown that conventional mass spectrometry workflows without Proteograph achieve approximately 10–15% of the protein coverage achieved with Proteograph. The Proteograph makes thousands of additional proteins accessible for biological investigation.

• PRECISE investigators identified more than 4,200 proteins with significant associations between nearby genetic variation and protein abundance, or cis-pQTLs. They reported 2,762 genetic–protein associations not previously reported across 12 reference studies and linked proteins to 71 health-related traits, illustrating the discovery potential of deep proteomics at population scale.

• In an independent study published in

Clinical Proteomics, CHA University researchers compared seven plasma preparation approaches. Proteograph XT delivered the greatest coverage, averaging approximately 6,060 proteins per sample, and the lowest rate of missing protein measurements, at 1.9%.

• Korea University Professors Sang-Won Lee and Jaewoo Kang presented preliminary findings from more than 5,500 plasma samples at ASMS and HUPO 2026. Their ID-Free AI Proteomics approach used identified and unidentified spectral signals generated with Proteograph and mass spectrometry, improving overall cancer-classification performance compared with models using identified-peptide features alone.

Third Quarter 2026 Financial Results

Revenue was $4.0 million for the third quarter of 2026, compared with $3.1 million in the second quarter of 2026 and $4.1 million in the third quarter of 2025. Revenue decreased 3% from the prior-year period. Product revenue was $2.8 million, consisting of sales of Proteograph instruments and consumable kits. Service revenue was $1.1 million, related party revenue was $0.1 million, and other revenue was approximately $67,000.

Gross profit was $1.9 million and gross margin was 47% for the third quarter of 2026.

Operating expenses were $16.5 million for the third quarter of 2026, including $1.2 million in stock-based compensation, compared with $21.5 million for the corresponding prior-year period, including $3.6 million in stock-based compensation. Operating expenses decreased 23%, primarily reflecting lower employee compensation expenses, including stock-based compensation.

Net loss was $13.7 million for the third quarter of 2026, compared with $18.2 million for the corresponding prior-year period.

For the nine months ended September 30, 2026, net cash used in operating activities was approximately $34.5 million. After deducting approximately $311,000 of net purchases of property and equipment, free cash flow was approximately negative $34.8 million. Free cash flow is a non-GAAP financial measure, defined as net cash used in operating activities less net purchases of property and equipment.... (truncated)nd investments were approximately $198.1 million as of September 30, 2026.

Capital Allocation

Through September 30, 2026, Seer had repurchased approximately 13.5 million Class A common shares at a weighted average price of $1.85 per share, using approximately $25 million of the combined $50 million authorized by the Board in May 2024 and February 2026. Approximately $25 million remained available under those authorizations. During the third quarter, the Company repurchased approximately 61,000 shares at a weighted-average price of $1.64 per share.

Seer’s capital allocation approach combines investment in commercial adoption and product innovation with disciplined spending and share repurchases. Based on its current operating plan, the Company believes it has sufficient capital to reach cash flow breakeven.

2026 Guidance

Seer now expects full-year 2026 revenue to be in the range of $13.5 million to $14.5 million, compared with the prior range of $16 million to $18 million. Continued pressure on academic and government funding has extended sales cycles, and several late-stage opportunities are now expected to close later than planned.

Webcast Information

Seer will host a conference call to discuss the third quarter 2026 financial results on Tuesday, November 10, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended September 30, — (in thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Product2,7602,7567,1938,372
Service1,0649132,2832,913
Related party90300146761
Other67152254331
Total revenue3,9814,1219,87612,377
Cost of revenue:
Product1,4111,3273,8173,868
Service3923359091,261
Related party828588224
Other217264695742
Total cost of revenue2,1022,0115,5096,095
Gross profit1,8792,1104,3676,282
Operating expenses:
Research and development6,43910,79723,45434,132
Selling, general and administrative10,10710,65929,67732,757
Total operating expenses16,54621,45653,13166,889
Loss from operations-14,667-19,346-48,764-60,607
Other income (expense):
Interest income1,9612,7656,2388,974
Loss on equity method investment-1,392-1,419-5,208-4,835
Other income (expense)365-210284-965
Total other income9341,1361,3143,174
Loss before provision for income taxes-13,733-18,210-47,450-57,433
Provision for income taxes52424173
Net loss-13,738-18,234-47,474-57,606
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities-410124-1,205295
Comprehensive loss-14,148-18,110-48,679-57,311
Net loss per share attributable to Class A and Class B common stockholders, basic and diluted-0.25-0.32-0.85-0.99
Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted55,562,07156,312,29055,572,43957,928,898

Balance Sheet

September 30, 2026 — (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents29,31647,285
Short-term investments126,581138,612
Accounts receivable, net2,7174,282
Related party receivables146300
Other receivables9641,370
Inventory6,3967,795
Prepaid expenses and other current assets1,7771,890
Total current assets167,897201,534
Long-term investments42,19054,686
Operating lease right-of-use assets18,66320,488
Property and equipment, net11,03114,754
Restricted cash524524
Other assets1,4944,097
Total assets241,799296,083
Current liabilities:
Accounts payable2,5835,611
Accrued expenses4,0707,135
Deferred revenue482341
Operating lease liabilities, current2,7862,575
Other current liabilities2129
Total current liabilities9,94215,691
Operating lease liabilities, net of current portion18,95621,077
Other noncurrent liabilities108
Total liabilities28,90836,776
Stockholders’ equity:
Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 55,809,767 and 56,219,599 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively11
Additional paid-in capital727,082724,819
Accumulated other comprehensive gain (loss)-746459
Accumulated deficit-513,446-465,972
Total stockholders’ equity212,891259,307
Total liabilities and stockholders’ equity241,799296,083

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s revenue guidance; the adoption and use of Seer’s products; expansion within customer accounts, sample volumes, repeat purchases and revenue growth; anticipated sample shipments under customer agreements; the potential applications of proteomic data in AI-driven research; capital allocation, share repurchases and the sufficiency of capital to reach cash flow breakeven under the current operating plan; and the enforcement of intellectual property rights, including the expected timing and outcome of the ITC proceeding. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:

Patrick Schmidt pr@seer.bio

Investor Contact:

Marissa Bych investor@seer.bio

SEER, INC.

Condensed Consolidated Statements of O perations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)

SEER, INC.

Condensed Consolidated

Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Seer earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.